RESUMEN
BACKGROUND: Docosahexaenoic acid (DHA) kinetics appear to change with intake, which is an effect that we studied in an older population by using uniformly carbon-13-labeled DHA ((13)C-DHA). OBJECTIVE: We evaluated the influence of a fish-oil supplement over 5 mo on the kinetics of (13)C-DHA in older persons. DESIGN: Thirty-four healthy, cognitively normal participants (12 men, 22 women) aged between 52 and 90 y were recruited. Two identical kinetic studies were performed, each with the use of a single oral dose of 40 mg (13)C-DHA. The first kinetic study was performed before participants started taking a 5-mo supplementation that provided 1.4 g DHA/d plus 1.8 g eicosapentaenoic acid (EPA)/d (baseline); the second study was performed during the final month of supplementation (supplement). In both kinetic studies, blood and breath samples were collected ≤8 h and weekly over 4 wk to analyze (13)C enrichment. RESULTS: The time × supplement interaction for (13)C-DHA in the plasma was not significant, but there were separate time and supplement effects (P < 0.0001). The area under the curve for plasma (13)C-DHA was 60% lower while subjects were taking the supplement than at baseline (P < 0.0001). The uniformly carbon-13-labeled EPA concentration was 2.6 times as high 1 d posttracer while patients were taking the supplement as it was at baseline. The mean (±SEM) plasma (13)C-DHA half-life was 4.5 ± 0.4 d at baseline compared with 3.0 ± 0.2 d while taking the supplement (P < 0.0001). Compared with baseline, the mean whole-body half-life was 61% lower while subjects were taking the supplement. The loss of (13)C-DHA through ß-oxidation to carbon dioxide labeled with carbon-13 increased from 0.085% of dose/h at baseline to 0.208% of dose/h while subjects were taking the supplement. CONCLUSIONS: In older persons, a supplement of 3.2 g EPA + DHA/d increased ß-oxidation of (13)C-DHA and shortened the plasma (13)C-DHA half-life. Therefore, when circulating concentrations of EPA and DHA are increased, more DHA is available for ß-oxidation. This trial was registered at clinicaltrials.gov as NCT01577004.
Asunto(s)
Suplementos Dietéticos , Ácidos Docosahexaenoicos/administración & dosificación , Aceites de Pescado/administración & dosificación , Anciano , Anciano de 80 o más Años , Trastornos del Conocimiento/prevención & control , Ácidos Docosahexaenoicos/sangre , Ácidos Docosahexaenoicos/farmacocinética , Ácido Eicosapentaenoico/administración & dosificación , Ácido Eicosapentaenoico/sangre , Ácido Eicosapentaenoico/farmacocinética , Femenino , Aceites de Pescado/sangre , Aceites de Pescado/farmacocinética , Estudios de Seguimiento , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The aim of this study was to investigate the effect of vegetable oil enrichment of retinal pigment epithelial (RPE) cells on their biochemical and biophysical properties. For this, RPE cells were incubated with 4 different vegetables oils (olive oil, corn oil, argan oil, and camelina oil). The cytotoxicity of these vegetable oils was assessed in vivo on 8-week-old mice and in vitro by using the neutral red and YO-PRO-1 tests. Membrane fluidity was evaluated by fluorescence anisotropy using the fluorescent probe diphenylhexatriene, and membrane fatty acid composition was assessed by gas chromatography. None of the oils tested displayed cytotoxic effects. In vitro, omega-3 rich oils improved membrane fluidity by 47% compared with the control cells. The omega-3 PUFA content within membranes decreased by 38% to 55% when cells were incubated separately with olive oil, corn oil, or argan oil, and increased when cells were incubated with a mixture of those oils, or with camelina oil alone (50% and 103% increase, respectively). Our results show that the fatty acids in vegetable oil incorporate into retinal cells and increase the plasma membrane fluidity.
Asunto(s)
Membrana Celular/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Ácidos Grasos Omega-3/farmacología , Aceites de Plantas/farmacología , Epitelio Pigmentado de la Retina/efectos de los fármacos , Animales , Línea Celular , Membrana Celular/metabolismo , Supervivencia Celular/efectos de los fármacos , Aceite de Maíz/farmacología , Células Epiteliales/metabolismo , Ácidos Grasos Omega-3/metabolismo , Ácidos Grasos Omega-3/toxicidad , Femenino , Humanos , Masculino , Fluidez de la Membrana/efectos de los fármacos , Lípidos de la Membrana/metabolismo , Ratones , Aceite de Oliva , Aceites de Plantas/metabolismo , Aceites de Plantas/toxicidad , Epitelio Pigmentado de la Retina/metabolismoRESUMEN
OBJECTIVE: In humans consuming a normal diet, we investigated 1) the capacity of a medium-chain triacylglycerol (MCT) supplement to stimulate and sustain ketonemia, 2) ¹³C-ß-hydroxybutyrate and ¹³C-trioctanoate metabolism, and 3) the theoretical contribution of the degree of ketonemia achieved to brain energy metabolism. METHODS: Eight healthy adults (26 ± 1 y old) were given an MCT supplement for 4 wk (4 times/d; total of 20 g/d for 1 wk followed by 30 g/d for 3 wk). Ketones, glucose, triacylglycerols, cholesterol, free fatty acids, and insulin were measured over 8 h during two separate metabolic study days before and after MCT supplementation. Using isotope ratio mass spectroscopy, ¹³C-D-ß-hydroxybutyrate and ¹³C-trioctanoate ß-oxidation to ¹³CO2 was measured over 12 h on the pre- and post-MCT metabolic study days. RESULTS: On the post-MCT metabolic study day, plasma ketones (ß-hydroxybutyrate plus acetoacetate) peaked at 476 µM, with a mean value throughout the study day of 290 µM. Post-MCT, ¹³C-trioctanoate ß-oxidation was significantly lower 1 to 8 h later but higher 10 to 12 h later. MCT supplementation did not significantly alter ¹³C-D-ß-hydroxybutyrate oxidation. CONCLUSIONS: This MCT supplementation protocol was mildly and safely ketogenic and had no side effects in healthy humans on their regular diet. This degree of ketonemia is estimated to contribute up to 8% to 9% of brain energy metabolism.
Asunto(s)
Encéfalo/metabolismo , Dieta Cetogénica/métodos , Suplementos Dietéticos , Metabolismo Energético , Cetosis/etiología , Neuronas/metabolismo , Triglicéridos/metabolismo , Ácido 3-Hidroxibutírico/sangre , Ácido 3-Hidroxibutírico/metabolismo , Acetoacetatos/sangre , Acetoacetatos/metabolismo , Adulto , Caprilatos/metabolismo , Isótopos de Carbono , Dieta Cetogénica/efectos adversos , Suplementos Dietéticos/efectos adversos , Emulsiones , Femenino , Humanos , Cetosis/sangre , Cetosis/metabolismo , Cetosis/fisiopatología , Masculino , Peso Molecular , Nootrópicos/administración & dosificación , Nootrópicos/efectos adversos , Nootrópicos/química , Nootrópicos/metabolismo , Oxidación-Reducción , Índice de Severidad de la Enfermedad , Triglicéridos/administración & dosificación , Triglicéridos/efectos adversos , Triglicéridos/químicaRESUMEN
Alzheimer's disease (AD) is generally associated with lower omega-3 fatty acid intake from fish but despite numerous studies, it is still unclear whether there are differences in omega-3 fatty acids in plasma or brain. In matched plasma and brain samples provided by the Memory and Aging Project, fatty acid profiles were quantified in several plasma lipid classes and in three brain cortical regions. Fatty acid data were expressed as % composition and as concentrations (mg/dL for plasma or mg/g for brain). Differences in plasma fatty acid profiles between AD, mild cognitive impairment (MCI), and those with no cognitive impairment (NCI) were most apparent in the plasma free fatty acids (lower oleic acid isomers and omega-6 fatty acids in AD) and phospholipids (lower omega-3 fatty acids in AD). In brain, % DHA was lower only in phosphatidylserine of mid-frontal cortex and superior temporal cortex in AD compared to NCI (-14% and -12%, respectively; both p < 0.05). The only significant correlation between plasma and brain fatty acids was between % DHA in plasma total lipids and % DHA in phosphatidylethanolamine of the angular gyrus, but only in the NCI group (+0.77, p < 0.05). We conclude that AD is associated with altered plasma status of both DHA and other fatty acids unrelated to DHA, and that the lipid class-dependent nature of these differences reflects a combination of differences in intake and metabolism.
Asunto(s)
Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/patología , Encéfalo/metabolismo , Disfunción Cognitiva/sangre , Disfunción Cognitiva/patología , Ácidos Grasos/metabolismo , Anciano , Anciano de 80 o más Años , Ácidos Grasos/sangre , Ácidos Grasos Omega-3/sangre , Ácidos Grasos Omega-6 , Femenino , Humanos , Estudios Longitudinales , Masculino , Estadística como AsuntoRESUMEN
OBJECTIVES: We investigated whether a dietary supplement rich in eicosapentaenoic acid (EPA) increases fasting plasma ketones or postprandial ketone responses in healthy young and elderly subjects. METHODS: Ten young (22 +/- 1 y old) and 10 elderly (75 +/- 1 y old) subjects were recruited and participated in two identical study days, one before and one 6 wk after providing an EPA-enriched supplement (1.4 g/d of EPA and 0.2 g/d of docosahexaenoic acid). On the study days, blood samples were collected at fasting and every hour for 6 h after giving a breakfast. Fasting and postprandial plasma beta-hydroxybutyrate (beta-OHB), free fatty acid (FFA), triacylglycerol, glucose, and insulin responses were measured. Fatty acid profiles were assessed in fasting plasma samples before and after the EPA supplement. RESULTS: After the EPA supplement, postprandial plasma beta-OHB responses decreased by 44% in the young and by 24% in the elderly subjects, in addition to 20% and 34% lower FFA responses in the young and elderly adults, respectively. beta-OHB and FFAs were positively and significantly correlated in young but not in elderly subjects before and after the EPA supplement. In both groups, postprandial plasma triacylglycerols, glucose, and insulin were not significantly different after the intake of the EPA supplement. Before and after the EPA supplement, fasting plasma EPA was 50% higher in the elderly but increased by about five times in both groups after intake of the EPA supplement. CONCLUSION: Contrary to our expectations, EPA supplementation lowered postprandial beta-OHB response and, in the elderly subjects, the concentration of postprandial beta-OHB was not lowered after intake of the EPA supplement.
Asunto(s)
Ácido 3-Hidroxibutírico/sangre , Ácido Eicosapentaenoico/farmacología , Ácidos Grasos no Esterificados/sangre , Cetonas/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento/sangre , Envejecimiento/fisiología , Área Bajo la Curva , Glucemia/metabolismo , Suplementos Dietéticos , Ácido Eicosapentaenoico/administración & dosificación , Ayuno/sangre , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/farmacología , Femenino , Humanos , Insulina/sangre , Masculino , Periodo Posprandial , Triglicéridos/sangre , Adulto JovenRESUMEN
Little information is available concerning whether incorporation of dietary omega-3 fatty acids into plasma lipids changes during healthy aging. Elderly (74 +/- 4 years old) and young (24 +/- 2 years old) adults were given a fish oil supplement for 3 weeks that provided 680 mg/day of docosahexaenoic acid and 320 mg/day of eicosapentaenoic acid, followed by a 2 week wash-out period. Compliance was monitored by spiking the capsules with carbon-13 glucose, the excretion of which was measured in breath CO2. In response to the supplement, plasma docosahexaenoic acid rose 42% more in the elderly but eicosapentaenoic responded similarly in both groups. Despite raising docosahexaenoic acid intake by five to tenfold, the supplement did not raise plasma free docosahexaenoic acid (% or mg/dL) in either group. We conclude that healthy aging is accompanied by subtle but significant changes in DHA incorporation into plasma lipids.
Asunto(s)
Ácidos Grasos Omega-3/sangre , Aceites de Pescado/administración & dosificación , Adulto , Anciano , Suplementos Dietéticos , Ácidos Docosahexaenoicos/sangre , Ácido Eicosapentaenoico/sangre , Aceites de Pescado/farmacología , HumanosRESUMEN
OBJECTIVE: Due to its high content of lignans, alpha-linolenic acid and fiber, flaxseed may reduce cardiovascular disease risk in humans. The present study evaluated the effect of flaxseed on markers of cardiovascular disease risk in healthy menopausal women. METHODS: One hundred ninety-nine women were randomly assigned to consume 40 g daily of flaxseed or wheat germ placebo for 12 mo. Fatty acids, apolipoproteins A-1 and B, lipoprotein(a), low-density lipoprotein particle size, fibrinogen, C-reactive protein, insulin, and glucose were measured at baseline and at 12 mo. RESULTS: In total 179 women were available for the intention-to-treat analysis. Flaxseed increased plasma alpha-linolenic (P < 0.0001), docosapentaenoic (P = 0.001), and total omega-3 fatty (P = 0.0004) acids. Differences between flaxseed and wheat germ were observed for apolipoprotein A-1 (-0.10 +/- 0.26 g/L, P = 0.011) and apolipoprotein B (-0.05 +/- 0.16 g/L, P = 0.047). From baseline, flaxseed raised apolipoproteins A-1 and B by 4.4% (P = 0.006) and 3% (P = 0.054), whereas wheat germ increased these apolipoproteins by 11.6% (P < 0.0001) and 7% (P = 0.0001), respectively. Both treatments increased lipoprotein(a) (P < 0.0001) and decreased low-density lipoprotein peak particle size (P < 0.0001). CONCLUSION: In this large, long-term, placebo-controlled trial in healthy menopausal women, flaxseed increased some omega-3 fatty acids in plasma and had a limited effect on apolipoprotein metabolism.
Asunto(s)
Enfermedades Cardiovasculares/sangre , Suplementos Dietéticos , Ácidos Grasos Omega-3/análisis , Lino , Menopausia , Anciano , Apolipoproteína A-I/sangre , Apolipoproteína A-I/metabolismo , Apolipoproteínas B/sangre , Apolipoproteínas B/metabolismo , Biomarcadores/sangre , Glucemia/metabolismo , Proteína C-Reactiva/metabolismo , Método Doble Ciego , Ácidos Grasos Omega-3/sangre , Femenino , Fibrinógeno/metabolismo , Humanos , Insulina/sangre , Lipoproteínas LDL/sangre , Persona de Mediana Edad , Tamaño de la Partícula , Placebos , Quebec , TriticumRESUMEN
The maintenance of optimal cognitive function is a central feature of healthy aging. Impairment in brain glucose uptake is common in aging associated cognitive deterioration, but little is known of how this problem arises or whether it can be corrected or bypassed. Several aspects of the challenge to providing the brain with an adequate supply of fuel during aging seem to relate to omega-3 fatty acids. For instance, low intake of omega-3 fatty acids, especially docosahexaenoic acid (DHA), is becoming increasingly associated with several forms of cognitive decline in the elderly, particularly Alzheimer's disease. Brain DHA level seems to be an important regulator of brain glucose uptake, possibly by affecting the activity of some but not all the glucose transporters. DHA synthesis from either alpha-linolenic acid (ALA) or eicosapentaenoic acid (EPA) is very low in humans begging the question of whether these DHA precursors are likely to be helpful in maintaining cognition during aging. We speculate that ALA and EPA may well have useful supporting roles in maintaining brain function during aging but not by their conversion to DHA. ALA is an efficient ketogenic fatty acid, while EPA promotes fatty acid oxidation. By helping to produce ketone bodies, the effects of ALA and EPA could well be useful in strategies intended to use ketones to bypass problems of impaired glucose access to the brain during aging. Hence, it may be time to consider whether the main omega-3 fatty acids have distinct but complementary roles in brain function.